Lonza Receives Regulatory OK for $5.5-Billion Acquisition of Capsugel
By

Lonza has received all regulatory approvals for its proposed $5.5-billion acquisition of Capsugel, a contract provider of dosage forms. Lonza expects to close the transaction soon, subject to the satisfaction of customary closing conditions.

With the acquisition of Capsugel, Lonza, a contract manufacturer of active pharmaceutical ingredients (small molecules and biologics), positions itself in the drug-product services sector by gaining oral dosage delivery technologies, including a position in hard-capsule technologies.

In December 2016, Lonza agreed to acquire Capsugel from the private-equity firm KKR for $5.5 billion in cash, including refinancing of existing Capsugel debt of approximately $2 billion. The acquisition followed Lonza’s opening in November 2016 of a new 1,300-square-meter facility in Basel, Switzerland with drug-product services laboratories with an initial focus on formulation development, drug product analytical development, and quality control. The new facility’s services include options for monoclonal antibodies, other biologics, drug conjugates, peptides, and small molecules that require a parenteral dosage form with the following services: particle testing, container-closure integrity testing, and detection of trace impurities in pharmaceutical products, such as extractables and leachables from plastics used in manufacturing.

Capsugel has made recent investments. In 2016, it made several key acquisitions: Xcelience, a Florida-headquartered contract development and manufacturing organization specializing in clinical trial material supply and small-scale commercial manufacturing, and Powdersize, a Quakertown, Pennsylvania-based specialist in micronization. In 2015, it completed construction of a new pharmaceutical spray-dried dispersion (SDD) commercial manufacturing facility at its site in Bend, Oregon. The completion represented the final phase of a two-year, $25-million investment to expand its commercial SDD capability at the site. In 2015, it announced plans to invest more than $25 million to increase production capacity and deliver further quality enhancements for its vegetarian capsules.

Source: Lonza

Leave a Reply

Your email address will not be published.